Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | CASP1 | P29466 | 1/20 | 0.58 |
| ▸ | CASP7 | P55210 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL112708 | 0.89 | CYP1A2 (1.00) | CYP1A2CYP2C9CYP2C19ALDH1A1MEN1 | |
| SCHEMBL31510123 | 0.88 | CYP1A2 (0.70) | CYP1A2CYP2C9CYP2C19ALDH1A1MEN1 | |
| SCHEMBL1341248 | 0.88 | CYP1A2 (0.89) | CYP1A2CYP2C9CYP2C19ALDH1A1MEN1 | |
| SCHEMBL864648 | 0.86 | CYP1A2 (0.72) | CYP1A2CYP2C9CYP2C19ALDH1A1MAPT | |
| SCHEMBL29708563 | 0.86 | CYP1A2 (0.72) | CYP1A2CYP2C9CYP2C19ALDH1A1MAPT | |
| SCHEMBL3523843 | 0.86 | CYP1A2 (0.85) | CYP1A2CYP2C9CYP2C19ALDH1A1MEN1 | |
| SCHEMBL8389395 | 0.86 | CYP1A2 (0.85) | CYP1A2CYP2C9CYP2C19ALDH1A1MEN1 | |
| SCHEMBL5085710 | 0.86 | CYP1A2 (0.85) | CYP1A2CYP2C9CYP2C19ALDH1A1MEN1 | |
| SCHEMBL21694180 | 0.86 | CYP1A2 (0.85) | CYP1A2CYP2C9CYP2C19ALDH1A1MEN1 | |
| SCHEMBL10408892 | 0.86 | CYP1A2 (0.85) | CYP1A2CYP2C9CYP2C19ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110551054-A | maleimide derivative, and preparation method and application thereof | TECHNICAL INST PHYSICS & CHEMISTRY CAS | 2019-12-10 | — | — | CN | claimed |
| WO-2009143405-A2 | SYNTHESIS OF GRAPHENE SHEETS AND NANOPARTICLE COMPOSITES COMPRISING SAME | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2009-11-26 | — | — | WO | claimed |
| US-20090264412-A1 | Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | claimed |
| US-20090137574-A1 | Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and Disorders | NOVO NORDISK A/S (DK) | 2009-05-28 | — | — | US | claimed |
| US-20080108598-A1 | Pharmaceutical use of substituted amides | NOVO NORDISK A/S (DK) | 2008-05-08 | — | — | US | claimed |
| EP-1862181-A2 | Combination therapy using an 11B-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | NOVO NORDISK A/S (DK) | 2007-12-05 | — | — | EP | claimed |
| EP-1854487-A2 | Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist | Novo Nordisk A/S (DK) | 2007-11-14 | — | — | EP | claimed |
| US-20060111366-A1 | Pharmaceutical use of substituted amides | NOVO NORDISK A/S (DK) | 2006-05-25 | — | — | US | claimed |
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | NOVO NORDISK A/S (DK) | 2006-05-25 | — | — | US | claimed |
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HIGH POINT PHARMACEUTICALS, LLC | 2006-05-04 | — | — | US | claimed |
| EP-1615667-A2 | COMBINATIONS OF AN 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| EP-1615666-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| EP-1615698-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| WO-2004089416-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089470-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089415-A2 | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| EP-0782151-B1 | Method of manufacturing an improved electrically conductive polymer, its use in the manufacture of electric cable and cable manufactured by this method | NEXANS (FR) | 2002-02-13 | — | — | EP | claimed |
| EP-0828345-A1 | Electrical conductor protected against electromagnetic disturbances exceeding a threshold | Alcatel Cable France (FR) | 1998-03-11 | — | — | EP | claimed |
| EP-0782151-A1 | Method of manufacturing an improved electrically conductive polymer, its use in the manufacture of electric cable and cable manufactured by this method | ALCATEL (FR) | 1997-07-02 | — | — | EP | claimed |
| JP-11021273-A | — | — | None | — | — | JP | disclosed |
| CN-116018381-B | Polarizing film, polarizing plate and liquid crystal display device containing azo compound or salt thereof | 日本化药株式会社 | 2025-05-02 | — | — | CN | disclosed |
| CN-119677819-A | Azo compound or salt thereof, and polarizing film, polarizing plate and liquid crystal display device each containing the same | 日本化药株式会社 | 2025-03-21 | — | — | CN | disclosed |
| CN-114945636-B | Azo compound or salt thereof, polarizing film, polarizing plate, and display device | 日本化药株式会社 | 2024-07-12 | — | — | CN | disclosed |
| CN-114008143-B | Azo compound, polarizing film containing the same, and polarizing plate | 日本化药株式会社 | 2024-05-14 | — | — | CN | disclosed |
| WO-2024043261-A1 | AZO COMPOUND OR SALT THEREOF, AND POLARIZING FILM, POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY DEVICE COMPRISING SAME | 日本化薬株式会社 | 2024-02-29 | — | — | WO | disclosed |
| CN-110499164-B | Liquid crystal alignment agent, liquid crystal alignment film and liquid crystal display element | 奇美实业股份有限公司 | 2023-12-05 | — | — | CN | disclosed |
| WO-2023200441-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| CN-113574041-B | Bisphenol production method and polycarbonate resin production method | 三菱化学株式会社 | 2023-10-13 | — | — | CN | disclosed |
| CN-116617868-A | High-strength anti-pollution graphene composite separation membrane and preparation method thereof | 深圳市君脉膜科技有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-107880902-B | Liquid crystal alignment agent, liquid crystal alignment film and liquid crystal display assembly | 奇美实业股份有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-116261924-A | Polarizing element, polarizing plate, and display device provided with same | 日本化药株式会社 | 2023-06-13 | — | — | CN | disclosed |
| CN-116097135-A | Polarizing element, polarizing plate, and display device provided with same | 日本化药株式会社 | 2023-05-09 | — | — | CN | disclosed |
| CN-116018381-A | Polarizing film, polarizing plate and liquid crystal display device containing azo compound or salt thereof | 日本化药株式会社 | 2023-04-25 | — | — | CN | disclosed |
| CN-108003896-B | Liquid crystal alignment agent, liquid crystal alignment film and liquid crystal display element | 奇美实业股份有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-114945636-A | Azo compound or salt thereof, and dye-based polarizing film, dye-based polarizing plate, and display device containing the same | 日本化药株式会社 | 2022-08-26 | — | — | CN | disclosed |
| CN-111433290-B | Azo compound or salt thereof, and polarizing element, polarizing plate and display device each comprising the same | 日本化药株式会社 | 2022-06-14 | — | — | CN | disclosed |
| CN-109085722-B | Method for manufacturing liquid crystal alignment film and liquid crystal display element | 奇美实业股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| WO-2022071204-A1 | POLARIZING ELEMENT, POLARIZING PLATE AND DISPLAY DEVICE PROVIDED WITH SAME | 日本化薬株式会社 | 2022-04-07 | — | — | WO | disclosed |
| WO-2022071201-A1 | POLARIZING ELEMENT, POLARIZING PLATE, AND DISPLAY DEVICE PROVIDED WITH SAME | 日本化薬株式会社 | 2022-04-07 | — | — | WO | disclosed |
| WO-2022054786-A1 | POLARIZING FILM CONTAINING AZO COMPOUND OR SALT THEREOF, POLARIZING PLATE, AND LIQUID CRYSTAL DISPLAY DEVICE | 日本化薬株式会社 | 2022-03-17 | — | — | WO | disclosed |
| CN-112390811-B | Dithia-anthrone derivative and preparation method and application thereof | 中国科学院理化技术研究所 | 2022-03-04 | — | — | CN | disclosed |
| CN-114008143-A | Azo compound, polarizing film containing the same, and polarizing plate | 日本化药株式会社 | 2022-02-01 | — | — | CN | disclosed |
| CN-113795554-A | Achromatic polarizing element, and achromatic polarizing plate and display device using same | 日本化药株式会社 | 2021-12-14 | — | — | CN | disclosed |
| CN-109207170-B | Liquid crystal alignment agent, liquid crystal alignment film and liquid crystal display element | 奇美实业股份有限公司 | 2021-12-10 | — | — | CN | disclosed |
| CN-108884245-B | Polyimide film and method for producing same | 柯尼卡美能达株式会社 | 2021-10-29 | — | — | CN | disclosed |
| CN-113574041-A | Method for producing bisphenol and method for producing polycarbonate resin | 三菱化学株式会社 | 2021-10-29 | — | — | CN | disclosed |
| WO-2021153374-A1 | AZO COMPOUND OR SALT THEREOF, AND DYE-BASED POLARIZING FILM, DYE-BASED POLARIZING PLATE AND DISPLAY DEVICE EACH CONTAINING SAME | 日本化薬株式会社 | 2021-08-05 | — | — | WO | disclosed |
| CN-110249008-B | Azo compound or salt thereof, and dye-based polarizing film, dye-based polarizing plate, and liquid crystal display device each containing the same | 日本化药株式会社 | 2021-06-11 | — | — | CN | disclosed |
| CN-110551054-B | Maleimide derivative, and preparation method and application thereof | 中国科学院理化技术研究所 | 2021-04-02 | — | — | CN | disclosed |
| CN-112390811-A | Dithia-anthrone derivative and preparation method and application thereof | 中国科学院理化技术研究所 | 2021-02-23 | — | — | CN | disclosed |
| WO-2021015188-A1 | AZO COMPOUND, AND POLARIZING FILM AND POLARIZING PLATE INCLUDING SAME | 日本化薬株式会社 | 2021-01-28 | — | — | WO | disclosed |
| WO-2020230647-A1 | ACHROMATIC POLARIZER, ACHROMATIC POLARIZING PLATE USING SAME, AND DISPLAY DEVICE | 日本化薬株式会社 | 2020-11-19 | — | — | WO | disclosed |
| WO-2020189201-A1 | METHOD FOR PRODUCING BISPHENOL AND METHOD FOR PRODUCING POLYCARBONATE RESIN | 三菱ケミカル株式会社 | 2020-09-24 | — | — | WO | disclosed |
| CN-111433290-A | Azo compound or salt thereof, and polarizing element, polarizing plate and display device each containing the same | 日本化药株式会社 | 2020-07-17 | — | — | CN | disclosed |
| EP-2970248-B1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | DISCOVERYBIOMED INC (US) | 2020-04-22 | — | — | EP | disclosed |
| EP-2970248-B1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | DISCOVERYBIOMED INC (US) | 2020-04-22 | — | — | EP | disclosed |
| US-20200062749-A1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | THE NATIONAL INSTITUTES OF PHARMACEUTICAL RESEARCH AND DEVELOPMENT (NIP) (CN) | 2020-02-27 | — | — | US | disclosed |
| WO-2020032091-A1 | EPOXY COMPOUND, EPOXY RESIN, EPOXY RESIN COMPOSITION, CURED RESIN PRODUCT, PREPREG, FIBER-REINFORCED COMPOSITE MATERIAL, AND PRODUCTION METHOD FOR THESE | 帝人株式会社 | 2020-02-13 | — | — | WO | disclosed |
| WO-2020032090-A1 | EPOXY COMPOUND, EPOXY RESIN, EPOXY RESIN COMPOSITION, CURED RESIN PRODUCT, PREPREG, FIBER-REINFORCED COMPOSITE MATERIAL, AND PRODUCTION METHOD FOR THESE | 帝人株式会社 | 2020-02-13 | — | — | WO | disclosed |
| CN-110551054-A | maleimide derivative, and preparation method and application thereof | TECHNICAL INST PHYSICS & CHEMISTRY CAS | 2019-12-10 | — | — | CN | disclosed |
| US-10369145-B2 | Coumarin derivatives and methods of use in treating hyperproliferative diseases | DISCOVERYBIOMED, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10369145-B2 | Coumarin derivatives and methods of use in treating hyperproliferative diseases | DISCOVERYBIOMED, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10364234-B2 | Pyridinecarboxamide derivatives, preparation method thereof and pharmaceutical uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-07-30 | — | — | US | disclosed |
| CN-106520719-B | A kind of ω of S type-transaminase ATA-W12 and its gene and application | 华东理工大学 | 2019-06-07 | — | — | CN | disclosed |
| US-20170342059-A1 | PYRIDINECARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2017-11-30 | — | — | US | disclosed |
| US-9815825-B2 | Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders | DISCOVERYBIOMED, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815825-B2 | Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders | DISCOVERYBIOMED, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815825-B2 | Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders | DISCOVERYBIOMED, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9695133-B2 | Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-07-04 | — | — | US | disclosed |
| CN-106520719-A | S-shaped omega-transaminase ATA-W12 as well as gene and application thereof | 华东理工大学 | 2017-03-22 | — | — | CN | disclosed |
| US-20160228437-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. | 2016-08-11 | — | — | US | disclosed |
| US-9370515-B2 | Mixed lineage kinase inhibitors and method of treatments | Califia Bio, Inc. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9315670-B2 | Composition for forming resist underlayer film and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-04-19 | — | — | US | disclosed |
| CN-105473550-A | Ido inhibitors | BRISTOL MYERS SQUIBB CO | 2016-04-06 | — | — | CN | disclosed |
| US-20160038475-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING HYPERPROLIFERATIVE DISEASES | DISCOVERYBIOMED, INC. (US) | 2016-02-11 | — | — | US | disclosed |
| US-20160038475-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING HYPERPROLIFERATIVE DISEASES | DISCOVERYBIOMED, INC. (US) | 2016-02-11 | — | — | US | disclosed |
| US-20160038475-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING HYPERPROLIFERATIVE DISEASES | DISCOVERYBIOMED, INC. (US) | 2016-02-11 | — | — | US | disclosed |
| US-20160024065-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | DISCOVERYBIOMED, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160024065-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | DISCOVERYBIOMED, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| EP-2970248-A2 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | Discoverybiomed Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970249-A2 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING HYPERPROLIFERATIVE DISEASES | Discoverybiomed Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| CN-105246887-A | Coumarin derivatives and methods of use in treating hyperproliferative diseases | DISCOVERYBIOMED INC | 2016-01-13 | — | — | CN | disclosed |
| CN-105131041-A | Novel triphenyl organic bismuth (V) complex catalyst, preparation method thereof, and catalysis application thereof in nitrogen-containing compounds | UNIV HUNAN | 2015-12-09 | — | — | CN | disclosed |
| CN-105121437-A | Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders | DISCOVERYBIOMED INC | 2015-12-02 | — | — | CN | disclosed |
| US-RE45670-E1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| US-20150175558-A1 | QUINAZOLINONE-BASED ONCOGENIC-RAS-SELECTIVE LETHAL COMPOUNDS AND THEIR USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-25 | — | — | US | disclosed |
| WO-2014152278-A2 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING HYPERPROLIFERATIVE DISEASES | DISCOVERYBIOMED, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152278-A2 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING HYPERPROLIFERATIVE DISEASES | DISCOVERYBIOMED, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152213-A2 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | DISCOVERYBIOMED, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140256733-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140235796-A1 | COMPOSITION FOR FORMING RESIST UNDERLAYER FILM AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-08-21 | — | — | US | disclosed |
| US-8809365-B2 | 1-substituted 2-azabicyclo [3.1.1] heptyl derivatives useful as nicotinic acetylcholine receptor modulators for treating neurologic disorders | UNIVERSITEIT GENT (BE) | 2014-08-19 | — | — | US | disclosed |
| US-8623857-B2 | N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 | MERCK SHARP & DOHME CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| CN-101130526-B | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK AS | 2013-07-10 | — | — | CN | disclosed |
| US-20130079326-A1 | N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | MERCK SHARP & DOHME CORP. | 2013-03-28 | — | — | US | disclosed |
| US-8404036-B2 | Water-soluble near-infrared absorbing coloring matters and aqueous inks containing same | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2013-03-26 | — | — | US | disclosed |
| WO-2012133936-A1 | CATALYST FOR PRODUCING ETHYLENE-BASED POLYMER AND METHOD FOR PRODUCING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012133919-A1 | PROCESS FOR PRODUCING CATALYST FOR PRODUCING ETHYLENIC POLYMER, CATALYST FOR PRODUCING ETHYLENIC POLYMER AND PROCESS FOR PRODUCING ETHYLENIC POLYMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-04 | — | — | WO | disclosed |
| US-20120245196-A1 | 1-SUBSTITUTED 2-AZABICYCLO [3.1.1] HEPTYL DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS FOR TREATING NEUROLOGIC DISORDERS | UNIVERSITEIT GENT (BE) | 2012-09-27 | — | — | US | disclosed |
| EP-2496579-A1 | 1-SUBSTITUTED 2-AZABICYCLO [3.1.1]HEPTYL DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS FOR TREATING NEUROLOGIC DISORDERS | Universiteit Gent (BE) | 2012-09-12 | — | — | EP | disclosed |
| CN-1945396-B | Liquid crystal display panel | IND TECH RES INST | 2012-08-29 | — | — | CN | disclosed |
| EP-2471533-A1 | Aryl carbonyl derivatives as therapeutic agents | Novo Nordisk A/S (DK) | 2012-07-04 | — | — | EP | disclosed |
| US-20120108533-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-05-03 | — | — | US | disclosed |
| EP-2424874-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL ANGENTS | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-03-07 | — | — | EP | disclosed |
| EP-2393360-A1 | PYRIDAZINONE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2011-12-08 | — | — | US | disclosed |
| US-8063081-B2 | N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-11-22 | — | — | US | disclosed |
| US-20110186789-A1 | SYNTHESIS OF GRAPHENE SHEETS AND NANOPARTICLE COMPOSITES COMPRISING SAME | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2011-08-04 | — | — | US | disclosed |
| EP-2331551-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | Boehringer Ingelheim International GmbH (DE) | 2011-06-15 | — | — | EP | disclosed |
| US-7960556-B2 | Thiadiazole derivatives for the treatment of neuro-degenerative diseases | NV REMYND (BE) | 2011-06-14 | — | — | US | disclosed |
| US-20110123784-A1 | WATER-SOLUBLE NEAR-INFRARED ABSORBING COLORING MATTERS AND AQUEOUS INKS CONTAINING SAME | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2011-05-26 | — | — | US | disclosed |
| WO-2011054885-A1 | 1-SUBSTITUTED 2-AZABICYCLO [3.1.1] HEPTYL DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS FOR TREATING NEUROLOGIC DISORDERS | UNIVERSITEIT GENT (BE) | 2011-05-12 | — | — | WO | disclosed |
| US-7897628-B2 | {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-03-01 | — | — | US | disclosed |
| EP-2094677-B1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | REMYND NV (BE) | 2011-01-12 | — | — | EP | disclosed |
| WO-2010125200-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL ANGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2010-11-04 | — | — | WO | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| EP-2239012-A2 | Pharmaceutical use of substituted amides | High Point Pharmaceuticals, LLC (US) | 2010-10-13 | — | — | EP | disclosed |
| WO-2010090737-A1 | PYRIDAZINONE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-12 | — | — | WO | disclosed |
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-06-10 | — | — | US | disclosed |
| US-20100143341-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-06-10 | — | — | US | disclosed |
| WO-2010023181-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-04 | — | — | WO | disclosed |
| WO-2009143405-A2 | SYNTHESIS OF GRAPHENE SHEETS AND NANOPARTICLE COMPOSITES COMPRISING SAME | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090264412-A1 | Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264414-A1 | Amide Derivatives and Pharmaceutical Use Thereof | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| EP-2094677-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV Remynd (BE) | 2009-09-02 | — | — | EP | disclosed |
| EP-1367132-B1 | PROCESS FOR PREPARATION OF OPTICALLY ACTIVE PROPOXYANILINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2009-08-12 | — | — | EP | disclosed |
| EP-1367132-B1 | PROCESS FOR PREPARATION OF OPTICALLY ACTIVE PROPOXYANILINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2009-08-12 | — | — | EP | disclosed |
| EP-2079738-A2 | 7-AZAINDOLE DERIVATIVES AS C-MET KINASE INHIBITORS | Glaxo Group Limited (GB) | 2009-07-22 | — | — | EP | disclosed |
| US-7541373-B2 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2009-06-02 | — | — | US | disclosed |
| US-20090137574-A1 | Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and Disorders | NOVO NORDISK A/S (DK) | 2009-05-28 | — | — | US | disclosed |
| EP-1603966-B1 | A PROCESS FOR PREPARATION OF POLYGLUTARIMIDE RESIN USING A FLUID OF SUPER CRITICAL CONDITION | LG CHEMICAL LTD (KR) | 2009-05-06 | — | — | EP | disclosed |
| US-7501405-B2 | Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-03-10 | — | — | US | disclosed |
| CN-100465286-C | Process for preparation of optically active propoxyaniline derivatives | DAIICHI SEIYAKU CO (JP) | 2009-03-04 | — | — | CN | disclosed |
| CN-100465286-C | Process for preparation of optically active propoxyaniline derivatives | DAIICHI SEIYAKU CO (JP) | 2009-03-04 | — | — | CN | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| US-7384967-B2 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-06-10 | — | — | US | disclosed |
| WO-2008061781-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2008-05-29 | — | — | WO | disclosed |
| US-20080119454-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| US-20080108598-A1 | Pharmaceutical use of substituted amides | NOVO NORDISK A/S (DK) | 2008-05-08 | — | — | US | disclosed |
| WO-2008049855-A2 | 7-AZAINDOLE DERIVATIVES AS C-MET KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-05-02 | — | — | WO | disclosed |
| EP-1899353-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DeveloGen Aktiengesellschaft (DE) | 2008-03-19 | — | — | EP | disclosed |
| CN-101130526-A | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK AS (DK) | 2008-02-27 | — | — | CN | disclosed |
| EP-1862181-A2 | Combination therapy using an 11B-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | NOVO NORDISK A/S (DK) | 2007-12-05 | — | — | EP | disclosed |
| EP-1854487-A2 | Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist | Novo Nordisk A/S (DK) | 2007-11-14 | — | — | EP | disclosed |
| EP-1854792-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007059905-A9 | THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES | DEVELOGEN AG (DE) | 2007-11-01 | — | — | WO | disclosed |
| EP-1603966-A4 | A PROCESS FOR PREPARATION OF POLYGLUTARIMIDE RESIN USING A FLUID OF SUPER CRITICAL CONDITION | LG CHEMICAL LTD (KR) | 2007-08-08 | — | — | EP | disclosed |
| CN-1328302-C | A process for preparation of polyglutarimide resin using a fluid of super critical condition | LG CHEMICAL LTD (KR) | 2007-07-25 | — | — | CN | disclosed |
| EP-1625170-B1 | A METHOD FOR PREPARING STYRENE AND MALEIMIDE COPOLYMER USING SUPER CRITICAL FLUID | LG CHEMICAL LTD (KR) | 2007-07-04 | — | — | EP | disclosed |
| WO-2007059905-A2 | THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2007-05-31 | — | — | WO | disclosed |
| US-7217560-B2 | Process for preparation of optically active propoxyaniline derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-15 | — | — | US | disclosed |
| US-7217560-B2 | Process for preparation of optically active propoxyaniline derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-15 | — | — | US | disclosed |
| US-7217560-B2 | Process for preparation of optically active propoxyaniline derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20070093610-A1 | Method for preparing styrene and maleimide copolymer using super critical fluid | LG CHEM, LTD. (KR) | 2007-04-26 | — | — | US | disclosed |
| CN-1948251-A | Preparation method of 2,3-difluoro alkoxy benzene | SHANGHAI KANGPENG CHEMICAL CO (CN) | 2007-04-18 | — | — | CN | disclosed |
| CN-1945396-A | Liquid crystal display panel | IND TECHNOLOGY INST (CN) | 2007-04-11 | — | — | CN | disclosed |
| WO-2006136402-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | disclosed |
| US-20060183783-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2006-08-17 | — | — | US | disclosed |
| EP-1625170-A4 | A METHOD FOR PREPARING STYRENE AND MALEIMIDE COPOLYMER USING SUPER CRITICAL FLUID | LG CHEMICAL LTD (KR) | 2006-08-02 | — | — | EP | disclosed |
| US-20060155075-A1 | Process for preparation of polyglutarimide resin using a fluid of super critical condition | LG CHEM, LTD. (KR) | 2006-07-13 | — | — | US | disclosed |
| EP-1367132-A4 | PROCESS FOR PREPARATION OF OPTICALLY ACTIVE PROPOXYANILINE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-20060111366-A1 | Pharmaceutical use of substituted amides | NOVO NORDISK A/S (DK) | 2006-05-25 | — | — | US | disclosed |
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | NOVO NORDISK A/S (DK) | 2006-05-25 | — | — | US | disclosed |
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HIGH POINT PHARMACEUTICALS, LLC | 2006-05-04 | — | — | US | disclosed |
| CN-1761697-A | Method for preparing polyglutarimide resin by using fluid under supercritical condition | LG CHEMICAL LTD (KR) | 2006-04-19 | — | — | CN | disclosed |
| EP-1625170-A2 | A METHOD FOR PREPARING STYRENE AND MALEIMIDE COPOLYMER USING SUPER CRITICAL FLUID | LG Chem, Ltd. (KR) | 2006-02-15 | — | — | EP | disclosed |
| EP-1615667-A2 | COMBINATIONS OF AN 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | disclosed |
| EP-1615666-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | disclosed |
| EP-1615698-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | disclosed |
| EP-1603966-A1 | A PROCESS FOR PREPARATION OF POLYGLUTARIMIDE RESIN USING A FLUID OF SUPER CRITICAL CONDITION | LG Chem, Ltd. (KR) | 2005-12-14 | — | — | EP | disclosed |
| EP-1531815-A1 | GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004101636-A2 | A METHOD FOR PREPARING STYRENE AND MALEIMIDE COPOLYMER USING SUPER CRITICAL FLUID | LG CHEM, LTD. (KR) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004089416-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089470-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089415-A2 | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004083281-A1 | A PROCESS FOR PREPARATION OF POLYGLUTARIMIDE RESIN USING A FLUID OF SUPER CRITICAL CONDITION | LG CHEM, LTD. (KR) | 2004-09-30 | — | — | WO | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
| CN-1496409-A | Process for preparation of optically active propoxyaniline derivatives | ��һ��������ҩ��ʽ���� | 2004-05-12 | — | — | CN | disclosed |
| CN-1496409-A | Process for preparation of optically active propoxyaniline derivatives | ��һ��������ҩ��ʽ���� | 2004-05-12 | — | — | CN | disclosed |
| US-20040077060-A1 | Process for preparation optically active propoxyaniline derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-22 | — | — | US | disclosed |
| US-20040077060-A1 | Process for preparation optically active propoxyaniline derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-22 | — | — | US | disclosed |
| US-20040077060-A1 | Process for preparation optically active propoxyaniline derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-22 | — | — | US | disclosed |
| WO-2004002481-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
| CN-1465653-A | Liquid crystal oriented film, and preparation and use thereof | 中国科学院化学研究所 | 2004-01-07 | — | — | CN | disclosed |
| EP-1367132-A1 | PROCESS FOR PREPARATION OF OPTICALLY ACTIVE PROPOXYANILINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
| EP-1367132-A1 | PROCESS FOR PREPARATION OF OPTICALLY ACTIVE PROPOXYANILINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
| EP-0743304-B1 | 4-(Arylaminomethylene)-2,4-dihydro-pyrazol-3-ones | MERCK PATENT GMBH (DE) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002070726-A1 | PROCESS FOR PREPARATION OF OPTICALLY ACTIVE PROPOXYANILINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-09-12 | — | — | WO | disclosed |
| EP-0782151-B1 | Method of manufacturing an improved electrically conductive polymer, its use in the manufacture of electric cable and cable manufactured by this method | NEXANS (FR) | 2002-02-13 | — | — | EP | disclosed |
| US-6034099-A | Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones | CELL PATHWAYS, INC. (US) | 2000-03-07 | — | — | US | disclosed |
| US-6015851-A | MELT PROCESSABILITY | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2000-01-18 | — | — | US | disclosed |
| EP-0965612-A1 | Rubber compositions containig bis anil compounds | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 1999-12-22 | — | — | EP | disclosed |
| EP-0961302-A2 | Electric coil, transformer, and electric motor having such coil | ALCATEL (FR) | 1999-12-01 | — | — | EP | disclosed |
| JP-H1121273-A | 4,4'-DIAMINODIPHENYL COMPOUND AND SALT THEREOF, AND PRODUCTION OF DYE/PIGMENT | DAINIPPON INK & CHEM INC | 1999-01-26 | — | — | JP | disclosed |
| EP-0828345-A1 | Electrical conductor protected against electromagnetic disturbances exceeding a threshold | Alcatel Cable France (FR) | 1998-03-11 | — | — | EP | disclosed |
| EP-0782151-A1 | Method of manufacturing an improved electrically conductive polymer, its use in the manufacture of electric cable and cable manufactured by this method | ALCATEL (FR) | 1997-07-02 | — | — | EP | disclosed |
| EP-0743304-A1 | 4-(Arylaminomethylene)-2,4-dihydro-pyrazol-3-ones | MERCK PATENT GmbH (DE) | 1996-11-20 | — | — | EP | disclosed |
| US-5028728-A | Process for the preparation of reaction products of 2,2-bis-(4-hydroxphenyl)-hexafluoropropane and new derivatives of this type | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-07-02 | — | — | US | disclosed |
| EP-0144730-B1 | 2-ANILINO-1,6-DIHYDRO-6-OXO-5-PYRIMIDINECARBOXYLIC ACID DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, AND ANTIALLERGIC AGENT CONTAINING THE SAME | MORISHITA PHARMACEUTICAL CO. LTD. (JP) | 1987-07-08 | — | — | EP | disclosed |
| EP-0144730-A1 | 2-Anilino-1,6-dihydro-6-oxo-5-pyrimidinecarboxylic acid derivatives, processes for the preparation thereof, and antiallergic agent containing the same | MORISHITA PHARMACEUTICAL CO. LTD. (JP) | 1985-06-19 | — | — | EP | disclosed |
| US-4345937-A | Herbicidal N-(haloacetyl)-N-(N'-methylenepyrrolidonyl)-2-alkoxyanilines | GAF CORPORATION (US) | 1982-08-24 | — | — | US | disclosed |
| US-4225335-A | HERBICIDES | VELSICOL CHEMICAL CORPORATION (US) | 1980-09-30 | — | — | US | disclosed |
| US-4216152-A | Process for making N-(N'-methylenepyrrolidonyl)-2-substituted anilines | GAF CORPORATION (US) | 1980-08-05 | — | — | US | disclosed |
| US-4178167-A | Herbicidal N-(haloacetyl)-N-(N'-methylenepyrrolidonyl)-2-alkoxyanilines useful as herbicides | GAF CORPORATION (US) | 1979-12-11 | — | — | US | disclosed |
| US-3954997-A | MITICIDES, INSECTICIDES | THE UPJOHN COMPANY (US) | 1976-05-04 | — | — | US | disclosed |
| US-3932378-A | Sulfonated disazo dyestuffs containing an ether group | CIBA-GEIGY AG (CH) | 1976-01-13 | — | — | US | disclosed |
| US-3932378-A | Sulfonated disazo dyestuffs containing an ether group | CIBA-GEIGY AG (CH) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (30 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024065-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | CFTR, SLC47A1, ABCB11 | CYP1A2 1524/4885CYP2C9 1787/4885CYP2C19 2058/4885 |
| US-20080108598-A1 | Pharmaceutical use of substituted amides | HSD11B1, HSD3B1, HSD11B2 | CYP1A2 79/4885CYP2C9 120/4885CYP2C19 68/4885 |
| US-20170342059-A1 | PYRIDINECARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USES THEREOF | KCNK2, KCNJ2, KCNK5 | CYP1A2 1242/4885CYP2C9 578/4885CYP2C19 572/4885 |
| US-20150175558-A1 | QUINAZOLINONE-BASED ONCOGENIC-RAS-SELECTIVE LETHAL COMPOUNDS AND THEIR USE | KRAS, KEAP1, NRAS | CYP1A2 2017/4885CYP2C9 2557/4885CYP2C19 2158/4885 |
| US-20160228437-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | MAP3K2, MAP3K1, MAP3K20 | CYP1A2 3032/4885CYP2C9 3970/4885CYP2C19 3599/4885 |
| US-10369145-B2 | Coumarin derivatives and methods of use in treating hyperproliferative diseases | HSP90B1, HSPD1, HSPE1 | CYP1A2 3271/4885CYP2C9 3882/4885CYP2C19 3716/4885 |
| US-20160038475-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING HYPERPROLIFERATIVE DISEASES | HSP90B1, HSPD1, HSPE1 | CYP1A2 3271/4885CYP2C9 3882/4885CYP2C19 3716/4885 |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | CYP1A2 2850/4885CYP2C9 4782/4885CYP2C19 4200/4885 |
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HSD11B1, HSD17B1, NR3C1 | CYP1A2 225/4885CYP2C9 987/4885CYP2C19 493/4885 |
| US-20140256733-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | MAP3K2, MAP3K1, MAP3K20 | CYP1A2 3032/4885CYP2C9 3970/4885CYP2C19 3599/4885 |
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | GCK, GCKR, PDK2 | CYP1A2 982/4885CYP2C9 1824/4885CYP2C19 1753/4885 |
| US-20090137574-A1 | Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and Disorders | HSD11B1, HSD11B2, HSD17B1 | CYP1A2 235/4885CYP2C9 608/4885CYP2C19 266/4885 |
| US-20120245196-A1 | 1-SUBSTITUTED 2-AZABICYCLO [3.1.1] HEPTYL DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS FOR TREATING NEUROLOGIC DISORDERS | CHRNA2, CHRNA10, CHRNA3 | CYP1A2 404/4885CYP2C9 961/4885CYP2C19 893/4885 |
| US-10364234-B2 | Pyridinecarboxamide derivatives, preparation method thereof and pharmaceutical uses thereof | KCNK2, KCNJ2, KCNK5 | CYP1A2 1242/4885CYP2C9 578/4885CYP2C19 572/4885 |
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | HSD11B1, HSD11B2, HSD17B1 | CYP1A2 235/4885CYP2C9 608/4885CYP2C19 266/4885 |
| US-20120108533-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | PNP, TYMP, MTAP | CYP1A2 3346/4885CYP2C9 3551/4885CYP2C19 3433/4885 |
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | CYP1A2 982/4885CYP2C9 1824/4885CYP2C19 1753/4885 |
| US-20060183783-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, PDK3, PDK4 | CYP1A2 788/4885CYP2C9 1584/4885CYP2C19 1549/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | CYP1A2 2850/4885CYP2C9 4782/4885CYP2C19 4200/4885 |
| US-20110123784-A1 | WATER-SOLUBLE NEAR-INFRARED ABSORBING COLORING MATTERS AND AQUEOUS INKS CONTAINING SAME | IK, RB1, COL1A1 | CYP1A2 487/4885CYP2C9 692/4885CYP2C19 887/4885 |
| US-20090264412-A1 | Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy | HSD11B1, HSD17B1, NR3C1 | CYP1A2 225/4885CYP2C9 987/4885CYP2C19 493/4885 |
| US-20100143341-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DTYMK, CMPK1, PDXK | CYP1A2 922/4885CYP2C9 782/4885CYP2C19 649/4885 |
| US-20090264414-A1 | Amide Derivatives and Pharmaceutical Use Thereof | HSD11B1, HSD11B2, HSD3B1 | CYP1A2 79/4885CYP2C9 120/4885CYP2C19 74/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | CYP1A2 2850/4885CYP2C9 4782/4885CYP2C19 4200/4885 |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | CYP1A2 982/4885CYP2C9 1824/4885CYP2C19 1753/4885 |
| US-20080119454-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | CYP1A2 982/4885CYP2C9 1824/4885CYP2C19 1753/4885 |
| US-20060111366-A1 | Pharmaceutical use of substituted amides | HSD11B1, HSD3B1, HSD11B2 | CYP1A2 79/4885CYP2C9 120/4885CYP2C19 68/4885 |
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | SNCA, PARK7, PRNP | CYP1A2 3341/4885CYP2C9 4583/4885CYP2C19 3887/4885 |
| US-20200062749-A1 | PYRROLO-AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | BTK, SYK, ITK | CYP1A2 2144/4885CYP2C9 1299/4885CYP2C19 616/4885 |
| US-20130079326-A1 | N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | PDPK1, PDK1, PDK3 | CYP1A2 3697/4885CYP2C9 3823/4885CYP2C19 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.